Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PDS Biotechnology CorpPDSB · Entity 7939 | Director | January 12, 2026 | March 03, 2026 |
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | Director | June 22, 2026 | June 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PDS Biotechnology Corp
Report date January 12, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2036-01-12 | Direct | 54,876 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 54,876 · Balance 54,876 F1: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date.
RIGEL PHARMACEUTICALS INC
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,125 |
Reported balance
After 2026-06-22 transaction · row 1
1 source rowRow 1 · 2026-06-22 · Sale · Disposed 2,500 · Balance 10,125 F1: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. F2: The shares sold in this transaction were sold to cover applicable tax withholding obligations incurred upon the vesting of restricted stock units and were not sold for investment purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025.
F2: The shares sold in this transaction were sold to cover applicable tax withholding obligations incurred upon the vesting of restricted stock units and were not sold for investment purposes.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aclaris Therapeutics, Inc.
Report date January 03, 2022 · Filed January 05, 2022
Section 16 reporting ended · disclosed 2022-01-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 160,214 |
Ending reported balance
After 2022-01-03 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2022-01-03 · Exercise / conversion · Acquired 3,875 · Balance 118,571 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Row 2 · 2022-01-03 · Exercise / conversion · Acquired 27,905 · Balance 146,476 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Row 3 · 2022-01-03 · Exercise / conversion · Acquired 6,638 · Balance 153,114 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Row 4 · 2022-01-03 · Exercise / conversion · Acquired 7,100 · Balance 160,214 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-01-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-01-03 · Exercise / conversion · Disposed 3,875 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2: Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited. F3: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-01-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-01-03 · Exercise / conversion · Disposed 27,905 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2: Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited. F4: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-01-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-01-03 · Exercise / conversion · Disposed 7,100 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2: Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited. F6: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-01-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-01-03 · Exercise / conversion · Disposed 6,638 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2: Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited. F5: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2: Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited.
F3: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
F4: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
F5: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
F6: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2018 Filed Dec 19, 2018 01:52 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 1,733 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-063369 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 12, 2018 Filed Jun 12, 2018 22:42 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 4,900 | $20.00 | $98,000.00 |
DisclosureSEC source: 0001209191-18-037311 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,636 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on March 23, 2018. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 22:42 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 100 | $20.00 | $2,000.00 |
DisclosureSEC source: 0001209191-18-037311 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,536 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on March 23, 2018. Read SEC document |
| May 18, 2018 Filed May 21, 2018 20:06 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 10,000 | $20.00 | $200,000.00 |
DisclosureSEC source: 0001209191-18-031804 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,636 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on March 23, 2018. Read SEC document |
| May 07, 2018 Filed May 9, 2018 20:17 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 6,933 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-028856 · doc4.xml · derivative · entry 3 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 Underlying: Common Stock · 6,933 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On December 15, 2016, the reporting person was granted 13,866 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: On December 15, 2016, the reporting person was granted 13,866 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| May 07, 2018 Filed May 9, 2018 20:17 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 1,974 | $18.10 | $35,729.40 |
DisclosureSEC source: 0001209191-18-028856 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,636 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| May 07, 2018 Filed May 9, 2018 20:17 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 6,933 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-028856 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 16, 2018 Filed Mar 20, 2018 21:02 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | OtherCommon Stock | 9,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-020920 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,677 F1 · kind: Pro rata distribution from NST, LLC, of which the reporting person is a non-managing member, in accordance with NST, LLC's Limited Liability Company Operating Agreement. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 15,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-007458 · doc4.xml · derivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock option (right to buy) · Derivative | 54,000 | $0.00 Strike: $22.09 | $0.00 |
DisclosureSEC source: 0001209191-18-007458 · doc4.xml · derivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2028-01-31 F1 · derivative.exercise_date: The option will vest over a period of four years, with 25% of the shares underlying the option vesting on the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 18, 2017 Filed Dec 21, 2017 21:56 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 1,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066818 · doc4.xml · derivative · entry 6 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,150 Underlying: Common Stock · 1,075 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On December 18, 2015, the reporting person was granted 4,300 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F4 · derivative.expiration_date: On December 18, 2015, the reporting person was granted 4,300 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| December 18, 2017 Filed Dec 21, 2017 21:56 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 327 | $24.12 | $7,887.24 |
DisclosureSEC source: 0001209191-17-066818 · doc4.xml · nonDerivative · entry 4 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,659 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| December 18, 2017 Filed Dec 21, 2017 21:56 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 1,075 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-066818 · doc4.xml · nonDerivative · entry 3 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,986 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 15, 2017 Filed Dec 21, 2017 21:56 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 1,733 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066818 · doc4.xml · derivative · entry 5 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,133 Underlying: Common Stock · 1,733 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On December 15, 2016, the reporting person was granted 13,866 restricted stock units, with 50% of the shares underlying the restricted stock units vesting in four equal annual installments beginning on December 15, 2017 and the other 50% of the shares underlying these restricted stock units vesting upon the achievement of a specified commercial milestone, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: On December 15, 2016, the reporting person was granted 13,866 restricted stock units, with 50% of the shares underlying the restricted stock units vesting in four equal annual installments beginning on December 15, 2017 and the other 50% of the shares underlying these restricted stock units vesting upon the achievement of a specified commercial milestone, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| December 15, 2017 Filed Dec 21, 2017 21:56 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 527 | $24.23 | $12,769.21 |
DisclosureSEC source: 0001209191-17-066818 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,911 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| December 15, 2017 Filed Dec 21, 2017 21:56 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 1,733 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-066818 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 18, 2016 Filed Dec 20, 2016 23:50 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 1,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-156176 · doc4.xml · derivative · entry 3 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,225 Underlying: Common Stock · 1,075 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On December 18, 2015, the reporting person was granted 4,300 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: On December 18, 2015, the reporting person was granted 4,300 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| December 18, 2016 Filed Dec 20, 2016 23:50 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 327 | $31.25 | $10,218.75 |
DisclosureSEC source: 0001209191-16-156176 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,705 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| December 18, 2016 Filed Dec 20, 2016 23:50 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 1,075 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-156176 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 22:21 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 13,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-155965 · doc4.xml · derivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,866 Underlying: Common Stock · 13,866 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: Subject to the reporting person's continuous service with the issuer as of the applicable vesting date, 50% of the shares underlying these restricted stock units will vest in four equal annual installments beginning on December 15, 2017 and the other 50% of the shares underlying these restricted stock units will vest upon the achievement of a specified commercial milestone. F3 · derivative.expiration_date: Subject to the reporting person's continuous service with the issuer as of the applicable vesting date, 50% of the shares underlying these restricted stock units will vest in four equal annual installments beginning on December 15, 2017 and the other 50% of the shares underlying these restricted stock units will vest upon the achievement of a specified commercial milestone. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 22:21 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantStock option (right to buy) · Derivative | 83,200 | $0.00 Strike: $28.92 | $0.00 |
DisclosureSEC source: 0001209191-16-155965 · doc4.xml · derivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,200 Underlying: Common Stock · 83,200 shares Expires 2026-12-14 F1 · derivative.exercise_date: The option will vest over a period of four years, with 25% of the shares underlying the option vesting on the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| October 26, 2016 Filed Oct 28, 2016 20:10 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionEmployee StockOption (right to buy) · Derivative | 3,912 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001209191-16-147288 · doc4.xml · derivative · entry 3 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,522 Underlying: Common Stock · 3,912 shares Expires 2024-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares underlying this option, representing a right to purchase a total of 10,434 shares, vested on December 8, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the issuer as of the applicable vesting date. Read SEC document |
| October 26, 2016 Filed Oct 28, 2016 20:10 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 3,912 | $21.83 | $85,398.96 |
DisclosureSEC source: 0001209191-16-147288 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,957 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 14, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.36 to $22.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 26, 2016 Filed Oct 28, 2016 20:10 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 3,912 | $1.52 | $5,946.24 |
DisclosureSEC source: 0001209191-16-147288 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 28, 2016 Filed Sep 28, 2016 22:10 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 1,841 | $24.66 | $45,399.06 |
DisclosureSEC source: 0001209191-16-143056 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,957 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 14, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.31 to $24.84, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 28, 2016 Filed Sep 28, 2016 22:10 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 1,841 | $0.72 | $1,325.52 |
DisclosureSEC source: 0001209191-16-143056 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 22:10 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionEmployee StockOption (right to buy) · Derivative | 1,841 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001209191-16-143056 · doc4.xml · derivative · entry 3 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,176 Underlying: Common Stock · 1,841 shares Expires 2024-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares underlying this option, representing a right to purchase a total of 4,017 shares, vested on August 13, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the issuer as of the applicable vesting date. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 23:07 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | OtherCommon Stock | 4,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142070 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,957 F2 · kind: Pro rata distribution from NST, LLC, of which the reporting person is a non-managing member, in accordance with NST, LLC's Limited Liability Company Operating Agreement. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 23:07 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | OtherCommon Stock | 50,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142070 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,167 F1 · kind: Liquidating distribution from NeXeption, LLC, of which the reporting person is a non-managing member, in accordance with NeXeption, LLC's Limited Liability Company Operating Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.